TET2 and aplastic anemia: C35 exhibits potent inhibitory effects on all members of the TET family.306,307 In contrast, the effects of auranofin and eltrombopag are specific to TET1 and TET2, respectively.308,309 Notably, eltrombopag, a nonpeptidyl thrombopoietin receptor agonist approved by the US FDA for use in patients with aplastic anemia as an iron chelator.310 Recently, Guan et al.309 reported the negative effects of eltrombopag on TET2.